UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 303

Sortiert nach

The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan

Pharmacoepidemiology and drug safety, 2019-05, Vol.28 (5), p.593-600

2019

Link zum Volltext

Verfügbarkeit prüfen

Current Trend in Antiviral Therapy for Chronic Hepatitis B

Viruses, 2022-02, Vol.14 (2), p.434

2022

Link zum Volltext

Verfügbarkeit prüfen

State-of-the-Art Chronic Hepatitis Viruses Research in Asia

Viruses, 2023-05, Vol.15 (5), p.1172

Chien, Rong-Nan

2023

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy

Journal of hepatology, 2012-08, Vol.57 (2), p.442-450

2012

Link zum Volltext

Verfügbarkeit prüfen

Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection

Alimentary pharmacology & therapeutics, 2023-10, Vol.58 (7), p.731-732

2023

Link zum Volltext

Verfügbarkeit prüfen

Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals

Alimentary pharmacology & therapeutics, 2024-03, Vol.59 (6), p.762-773

2024

Link zum Volltext

Verfügbarkeit prüfen

Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies

Liver international, 2022-03, Vol.42 (3), p.551-560

2022

Link zum Volltext

Verfügbarkeit prüfen

Higher HBeAg‐reversion virological relapse and lower sustained remission after treatment cessation in tenofovir‐treated HBeAg‐positive patients

Journal of medical virology, 2023-11, Vol.95 (11), p.e29213-e29213

2023

Link zum Volltext

Verfügbarkeit prüfen

Re‐treatment for severe hepatitis flare in HBeAg‐negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics

Journal of viral hepatitis, 2020-05, Vol.27 (5), p.544-547

2020

Link zum Volltext

Verfügbarkeit prüfen

Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients

Hepatology (Baltimore, Md.), 2013-12, Vol.58 (6), p.1888-1896

2013

Link zum Volltext

Verfügbarkeit prüfen

Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof‐of‐concept study

Hepatology research, 2022-10, Vol.52 (10), p.817-823

2022

Link zum Volltext

Verfügbarkeit prüfen

Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype

Cancer science, 2024-02, Vol.115 (2), p.564-574

2024

Link zum Volltext

Verfügbarkeit prüfen

Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis

Alimentary pharmacology & therapeutics, 2020-10, Vol.52 (8), p.1399-1406

2020

Link zum Volltext

Verfügbarkeit prüfen

A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off‐therapy relapse: An observational study

Journal of gastroenterology and hepatology, 2022-11, Vol.37 (11), p.2164-2172

2022

Link zum Volltext

Verfügbarkeit prüfen

Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population‐based cohort study

Journal of viral hepatitis, 2019-06, Vol.26 (6), p.718-726

2019

Link zum Volltext

Verfügbarkeit prüfen

Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy

Liver international, 2022-04, Vol.42 (4), p.945-946

2022

Link zum Volltext

Verfügbarkeit prüfen

Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy

The Lancet infectious diseases, 2021-07, Vol.21 (7), p.910-911

2021

Link zum Volltext

Verfügbarkeit prüfen

Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan

Alimentary pharmacology & therapeutics, 2020-12, Vol.52 (11-12), p.1695-1706

2020

Link zum Volltext

Verfügbarkeit prüfen

Finite nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B: From an “option” to an “active recommendation”

The Kaohsiung journal of medical sciences, 2022-04, Vol.38 (4), p.295-301

2022

Link zum Volltext

Verfügbarkeit prüfen

Characteristic geoepidemiology of primary biliary cholangitis in Taiwan: A nationwide population‐based study

Hepatology research, 2023-09, Vol.53 (9), p.866-877

2023

Link zum Volltext

Verfügbarkeit prüfen

The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B

Journal of viral hepatitis, 2021-03, Vol.28 (3), p.475-483

2021

Link zum Volltext

Verfügbarkeit prüfen

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Hepatology international, 2012-06, Vol.6 (3), p.531-561

2012

Link zum Volltext

Verfügbarkeit prüfen

Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B‐related compensated cirrhosis—authors' reply

Alimentary pharmacology & therapeutics, 2021-05, Vol.53 (9), p.1042-1043

2021

Link zum Volltext

Verfügbarkeit prüfen

A community-based study on the association between Helicobacter pylori Infection and obesity

Scientific reports, 2018-07, Vol.8 (1), p.10746-10, Article 10746

2018

Link zum Volltext

Verfügbarkeit prüfen

Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis

PloS one, 2019-11, Vol.14 (11), p.e0225482-e0225482

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 303

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(287)
Mit Volltextzugriff
(279)

Publikationsform

Sprache

Englisch
(302)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(227)
Life Sciences & Biomedicine
(205)
Humans
(160)
Male
(112)
Gastroenterology & Hepatology
(101)
Female
(95)
Middle Aged
(93)
Adult
(70)
Antiviral Agents - Therapeutic Use
(56)
Hepatitis B
(56)
Aged
(48)
Hepatitis
(48)
Hepatitis B, Chronic - Drug Therapy
(47)
Biological And Medical Sciences
(44)
Infectious Diseases
(44)
Liver Cirrhosis
(43)
Medical Sciences
(42)
Interferon
(41)
Hepatitis C
(40)
Patients
(40)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan

Current Trend in Antiviral Therapy for Chronic Hepatitis B

State-of-the-Art Chronic Hepatitis Viruses Research in Asia

Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy

Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection

Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals

Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies

Higher HBeAg‐reversion virological relapse and lower sustained remission after treatment cessation in tenofovir‐treated HBeAg‐positive patients

Re‐treatment for severe hepatitis flare in HBeAg‐negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics

Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients

Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof‐of‐concept study

Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype

Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis

A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off‐therapy relapse: An observational study

Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population‐based cohort study

Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy

Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy

Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan

Finite nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B: From an “option” to an “active recommendation”

Characteristic geoepidemiology of primary biliary cholangitis in Taiwan: A nationwide population‐based study

The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B‐related compensated cirrhosis—authors' reply

A community-based study on the association between Helicobacter pylori Infection and obesity

Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis

Suchergebnisse filtern